Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in OncologyH1 core operating income of €656m,...

Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025       Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day...